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A B S T R A C T
Purpose
This study was performed to examine the characteristics of transplant activity for patients with
myelodysplastic syndromes (MDS) older than 50 years within the European Group for Blood and
Marrow Transplantation, and to evaluate the factors predicting outcome within this group
of patients.
Patients and Methods
We performed a retrospective multicenter analysis of 1,333 MDS patients age 50 years or older
who received transplantation within the EBMT since 1998. The median recipient age was 56
years, with 884 patients (66%) age 50 to 60 years and 449 (34%) patients older than 60 years.
There were 811 HLA-matched sibling (61%) and 522 (39%) unrelated donor transplants. Five
hundred patients (38%) received standard myeloablative conditioning (SMC), and 833 (62%)
received reduced intensity conditioning (RIC).
Results
The 4-year estimate for overall survival of the whole cohort was 31%. On multivariate analysis, use
of RIC (hazard ratio [HR], 1.44; 95% CI, 1.13 to 1.84; P  .01) and advanced disease stage at
transplantation (HR, 1.51; 95% CI, 1.18 to 1.93; P  .01) were associated with an increased
relapse rate. In contrast, advanced disease stage at transplantation (HR, 1.43; 95% CI, 1.13 to
1.79; P  .01), use of an unrelated donor (P  .03), and RIC (HR, 0.79; 95% CI, 0.65 to 0.97;
P  .03) were independent variables associated with nonrelapse mortality. Advanced disease
stage at transplantation (HR, 1.55; 95% CI, 1.32 to 1.83; P  .01) was the major independent
variable associated with an inferior 4-year overall survival.
Conclusion
Allogeneic hematopoietic stem-cell transplantation remains a potential curative therapeutic option
for many older patients with MDS. In this analysis, disease stage at time of transplantation, but not
recipient age or the intensity of the conditioning regimens, was the most important factor
influencing outcomes.
J Clin Oncol 28:405-411. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Allogeneic hematopoietic stem-cell transplantation
(HSCT) is the only curative treatment for patients
withmyelodysplastic syndromes (MDS) or second-
ary acute myeloid leukemia (sAML). Early registry
studies demonstrated an adverse association be-
tween advanced age and increased nonrelapsemor-
tality (NRM).1-7 However, recent improvements in
conditioning regimens, supportive care, as well as
the introduction of reduced intensity conditioning
(RIC) regimens, have allowed the transplantation of
older patients.8,9 Concurrent improvements in the
resolution of HLA typing have facilitated the in-
creased use of unrelated donor transplantationwith
comparable results to sibling allografts. These devel-
opments have led to a significant increase in the
number of elderly patients withMDSbeing referred
for allogeneic transplantation.10
While much of the drive toward allografting
older patients has been made possible by the use of
RIC regimens, it remains unclear as to whether it
confers an improved overall survival (OS) in elderly
patients with MDS. Some studies have suggested
that the dose intensity of the conditioning regimen
appears to play an important role in relapse-free
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survival post-transplantation for MDS or AML11,12 and recent Euro-
pean Group for Blood andMarrow Transplantation (EBMT) studies
in MDS and multiple myeloma have indicated that while the use of
RIC is associated with a lower NRM, this is offset by a significantly
higher relapse incidence when compared with conventional myeloa-
blative conditioning regimens.6,13
With improvements in the quality of life and longevity of the
generalpopulation, increasingnumbersofpatientsolder than50years
are now being actively treated for MDS. Concurrent with these
changes in treatment expectations,many older patients now ask to be
considered for an allogeneic HSCT. The challenges facing transplant
physicians at present include deciding which older MDS patients
should be eligible for allografting, and whether certain older patients
may derive greater benefit from receiving an increased dose regimen.
Herein, we report on a retrospective multicenter analysis of 1,333
patients with MDS 50 years or older who received transplantation
within the EBMT since 1998. The main aims of this study were to
examine the characteristics of transplant activity for patients with
MDS older than 50 years within EBMT, and additionally to study the
factors predicting outcome within this group of patients.
PATIENTS AND METHODS
Patient details are presented in Table 1. Included in the studywere 1,333 patients
from 202 centers, with a primary diagnosis of MDS. Only data from patients
who underwent a first allogeneic transplantation between January 1998 and
October 2006 andwhowere registered in the EBMT registry were included in
this analysis. Data from 295 patients with HLA-matched sibling donors have
been reported in apreviousEBMTanalysis.6All patientswere 50years orolder
at time of their first allogeneic transplantation. Disease morphology was clas-
sified according to the French-American-British (FAB) classification and was
documented as separate variables for time of initial diagnosis as well as at time
of transplantation. Patients with a diagnosis of chronic myelomonocytic leu-
kemia (CMML) were excluded from the analysis. Three hundred thirteen
patients (24%) had refractory anemia/refractory anemia with ringed sider-
oblasts, 471 (35%) had refractory anemia with excess blasts, 215 (16%) had
refractory anemia with excess blasts in transition, and 334 secondary acute
myeloid leukemia (25%) at initial diagnosis. Disease status at transplantation
was defined as either early ( 5% marrow blasts) or advanced ( 5% mar-
row blasts).
The median recipient age was 56 years (range, 50 to 74 years) with 884
patients (66%) age 50 to 60 years and449 (34%) ageolder than60 years. There
were 811 HLA-matched sibling (67%) and 522 unrelated donor transplants
(33%). Four hundred nine were matched unrelated donors and 113 were
mismatchedunrelateddonors.Fivehundredpatients (38%)received standard
myeloablative conditioning (SMC) and 833 (62%) received RIC as previously
defined.6 Briefly, RIC included fludarabine plus intermediate doses of one or
two alkylating agents or low-dose total body irradiation (2 to 4 Gy), with or
without anti-thymocite globulin or alemtuzumab. Intermediate doses of alky-
lating agents were defined as busulphan (8 to 10 mg/kg orally), intravenous
melphalan (80 to 140 mg/m2), intravenous cyclophosphamide (600 to 1,200
mg/m2), or intravenous thiotepa (5 to 10mg/kg).
Themedian ageof theolder than60 cohortwas 63 years (range, 60 to 75)
comparedwith54years (range, 50 to60) for the50 to60cohort. Patients in the
older than 60 cohort were more likely to receive a volunteer unrelated donor
transplant (37% v 32%; P  .03), as well as a RIC regimen (78% v 55%;
P  .01), while patients in the 50 to 60 cohort were more likely to have
advanced stage MDS at transplant. Patients receiving RIC were older when
compared with SMC recipients (median age, 59 years [range, 50.0 to 74.7
years] v54years [range, 50.0 to73.7 years];P .02).However, SMCrecipients
had more advanced disease stage at both time of diagnosis (60% v 49%;
P .03) and at time of transplantation. Therewas no difference in donor type
between RIC and SMC (P .15).
For graft versus host disease prophylaxis, this variablewas not uniformly
entered into the EBMT database in most patients, and thus its impact on
transplantation outcomes has not been estimated. Fifty-one percent of pa-
tients received some form of in vivo T-cell depletion. Due to the retrospective
natureof the study, the reason(s) for inclusion in aRICprotocol andexclusion
fromaSMCineach transplantationgroupwerenotknown. Informedconsent
was obtained locally in accordance with the principles laid out in the Declara-
tion of Helsinki and based on specific protocols approved by the respective
local and national ethics committees for each transplant center.
Statistical Methods
End points were assessed on the date of last patient contact, and the final
database was updated in October 2006. Analysis focused on NRM, disease
relapse, or progression, relapse-free survival (RFS), and OS. Transplantation
outcomes were tabulated at 4-years after transplantation, although outcomes
at earlier time points are shown in Figure 1 where cumulative incidence
estimates are shown in a competing risk context.
The probabilities of RFS andOS estimates from the time of transplanta-
tion are identical to the usual Kaplan-Meier estimates and groups were com-
pared using the two-tailed log-rank test. The probability of occurrence of graft
Table 1. Patient Characteristics
Characteristic No. %
Median recipient age, years
Range
50-60 884 66
 60 449 34
Conditioning
Myeloablative 500 38
Reduced intensity 833 62
Donor type
HLA-matched sibling 811 61
HLA-matched unrelated 409 31
HLA-mismatched unrelated 113 8
Stem-cell source
Bone marrow 256 19
Peripheral blood 1077 81
Transplant period
1998-2001 395 30
2001 onward 938 70
Interval from diagnosis to transplantation, months
 6 455 34
6-12 428 32
 6 450 34
Disease stage at diagnosis
RA/RARS 313 24
RAEB 471 35
RAEB-t 215 16
sAML 334 25
Disease status at transplantation
Early 557 42
Advanced 688 52
Unavailable 88 6
Cytogenetics
Poor 89 7
Standard 91 7
Good 225 17
Unavailable 928 69
Abbreviations: RA, refractory anemia; RARS, refractory anemia with
ringed sideroblasts; RAEB, refractory anemia with excess blasts; RAEB-t,
refractory anemia with excess blasts in transition; sAML, secondary acute
myeloid leukemia.
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versus host disease, NRM, and disease relapse or progression was calculated
using cumulative incidence estimates, taking into account the appropriate
competing risk structure(s). (Cause specific) effect estimates for risk factors
were obtained using Cox regression models. The main variables analyzed
included donor age, donor status, recipient age group (50 to 60 v 60 years),
FAB disease classification at presentation, disease status at transplantation,
type of conditioning regimen, time period of transplantation (1998 to 2001 v
2001-present), time from diagnosis to transplantation ( 6 month, 6 to 12
months, and 12months), lines of prior intensive chemotherapy, cytogenet-
ics,donor-recipient cytomegalovirus status, graft type (bonemarrowvperiph-
eral blood stemcells). Therewas sufficient data on cytogenetics in 378patients
(31%). As such, International Prognostic Scoring System (IPSS) was not
included as a variable in this study.
Formultivariate analyses, themain covariateswere first entered together
into the model; with covariates found not to be significant at the .10 level
removed from theCoxmodel in a stepwise backwardway. Type of condition-
ing regimen was held in the model at each step irrespective of its significance
since it was themain parameter of interest. Potential interactions between the
covariate type of conditioning regimen and the other remaining covariates
were tested, adding cross-product terms to the model in a forward stepwise
way. Significance tests for all outcomes are based on the usual Cox models
which estimate cause-specific hazards and test hazard ratios (HRs) using a
likelihood ratio test.However,whenweproduced survival curves (cumulative
incidence estimates) these were based on uni- or bivariate competing risk
estimates without underlying model assumptions, but with unbiased curve
estimates. When groups were compared according to continuous covariates,
the Mann-WhitneyU test or Kruskal-Wallis one-way analysis of variance on
ranks testwere used for differences inmedians. According to the group sizes, a
2 analysisorFisher’s exact testwasused tocompare categoric covariates. SPSS
version 11 (SPSS, Chicago, IL) was used for all statistical analyses.
RESULTS
OS
The 4-year estimate OS of the whole cohort was 31% (Fig 1). At
the time of data censure, there were 642 deaths in total. The main
identifiable causes of death were relapse in 235 (37%), secondary
malignancy in three (0.5%), transplant-related causes 359 (56%),
and other causes 45 (7%). The 4-year OS estimate of the 50 to 60
years and older than 60 years cohort was 34% and 27%, respectively,
corresponding to aHR of 0.87 (P .23). In addition, 4-year estimate
OS for patients receivingRICor SMCwas 32%versus 30%(HR, 0.97;
P .73; Fig 2).
Nonrelapse Mortality
The 4-year estimate NRM was 36% for all patients. However,
patients undergoing RIC had a significantly lower 4-year NRMwhen
comparedwith those receiving SMC (32% v 44%;HR, 0.84; P .05).
While patients older than 60 years had a higher NRM, this was not
significantly different from the 50 to 60 age group (4-year estimate:
36% v 39%; HR, 1.11; P .39). When compared with the use of an
HLA-matched sibling donor, an HLA-matched or HLA-mismatched
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Fig 1. Stacked cumulative incidence curves from a competing risk model
evaluating the proportion of patients in a particular state with respect to the
presence or absence of relapse, as a function of time after transplant. OS,
overall survival.
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Fig 2. Stacked cumulative incidence
curves from a competing risk model with
relapse and death as competing risks,
with the study population substratified
according to (A) age 50 to 60 years, stan-
dard myeloablative conditioning (SMC),
(B) age  60 years, SMC, (C) age 50 to 60
years, reduced intensity conditioning (RIC),
and (D) age  60 years, RIC.
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unrelated donor was both associated with a higher NRM (4-year
estimate: 34% v 40% v 54%; P .02; Fig 3).
Relapse
There were 368 relapses in the cohort at time of data censure.
Despite more patients with advanced disease receiving SMC, patients
with RIC had a higher 4-year relapse rate (41% v 33%; HR, 1.39;
P .01). In addition, patients with advanced age had a higher relapse
rate (50 to 60 years: 32% v 60 years: 41%;HR, 1.32;P .02). There
was no significant difference in relapse incidence between patients
with either an HLA-matched sibling, HLA-matched or mismatched
unrelated donor (4-year estimate: 36% v 34% v 38%; P .96).
Cytogenetics
Based on the IPSS cytogenetic classification, 89 patients were
poor risk, 91 standard risk, and 225 favorable risk. There was no
significant difference in the choice of conditioning regimens between
different cytogenetic risk groups. Patients with available cytogenetic
data were more likely to be 50 to 60 years, have an HLA-matched
sibling donor, and have less advanced disease stage at time of trans-
plant. On univariate analysis, patients with poor risk cytogenetics had
a significantly increased 4-year relapse incidence (71% v 39% v 37%;
P .01) and reducedmedian OS (8.1 v 19.4 v 30.5 months; P .01)
whencomparedwithpatientswith standardor favorable cytogenetics.
There was no significant difference in 4-year NRM among groups
(42% v 35% v 36%; P .24).
Multivariate Analysis
On multivariate analysis of 4-year outcomes (Table 2), use of
RIC (HR, 1.44; 95%CI, 1.13 to 1.84; P .01) and advanced disease
stage at transplantation (HR, 1.51; 95% CI, 1.18 to 1.93; P  .01)
were associated with an increased relapse rate. In contrast, ad-
vanced disease stage at transplantation (HR, 1.43; 95% CI, 1.13 to
1.79; P .01), use of RIC (HR, 0.79; 95% CI, 0.65 to 0.97; P .03)
and use of an unrelated donor (P .03) were independent variables
associatedwithNRM.Advanced disease stage at transplantation (HR,
1.55; 95% CI, 1.32 to 1.83; P  .01) was the major independent
variable associated with an inferior 4-year OS.
DISCUSSION
The contribution of recipient age toward the outcomes of allogeneic
hematopoietic stem-cell transplantation has been a subject of signifi-
cant debate in recent years. The incidenceof poor riskMDS is propor-
tionally greater in elderly patients, with increased frequency of sAML,
as well as adverse cytogenetic abnormalities.3,7 Early registry studies
have demonstrated a significant correlation between advanced age
and increasedNRM.1-4,7,14,15 This study is the largest comparing out-
comesofpatientswithMDSolder than50yearsundergoingallogeneic
HSCT. Of note, while the study is based on the FAB classification of
MDS, based on the current WHO classification system, 41% of the
cohortwouldhaveAMLat timeof initial diagnosis. Therewere inher-
ent imbalances between the cohorts, with patients age 50 to 60 years
more likely to receive SMC, with a more advanced disease stage at
transplantation, while patients age older than 60 years were more
likely to have an unrelated donor. In addition, there are the usual
limitations of registry-based studies with the incompleteness of IPSS
and cytogenetic data.Nevertheless, onmultivariate analysis, therewas
no significant difference in outcomes between patients aged 50 to 60
yearswhencomparedwith thoseolder than60years. Importantly, at 4
years post-transplantation, 31% of the cohort was alive, indicating
that HSCT is a feasible therapeutic option in a significant proportion
of older patients undergoing an allograft forMDS.
With the implementation of reduced intensity conditioning reg-
imens, various groups have demonstrated that older patients with
MDS can be successfully allografted. Alyea and colleagues11 per-
formed a retrospective analysis of 152 patients withMDS/AML older
than 50 years undergoing RIC or myeloablative transplantation. De-
spite RIC patients being more likely to have unrelated donors and
active disease at transplantation, the OS was improved in the RIC
group, with the NRMmortality rate being lower for RIC patients but
with a higher relapse rate.16More recently, the EBMT reported on the
outcomes of 836 patients with MDS who received transplantation
with aHLA-identical sibling donor, analyzed according to the type of
conditioning received.6 Despite the fact that RIC patients were older
than patients in the SMC group, the 3-year probability of being pro-
gression free was similar, with an increased 3-year relapse rate after
RIC offset by a decreased 3-year NRM when compared with SMC.
Similarly, in this study, the use of RIC was associated with a higher
relapse rate. In contrast, advanced disease stage and the use of an
unrelateddonor, rather thanageor typeof conditioning regimenwere
the only independent factors influencing the NRM.
There is an increasing awareness that transplant physicians need
to consider both age as well as the coexistence of other comorbidities
in the evaluation of patient suitability for transplantation. This study
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Fig 3. Stacked cumulative incidence
curves from a competing risk model with
relapse and death as competing risks,
with the study population substratified
according to donor type: (A) HLA-matched
sibling, (B) HLA-matched unrelated donor.
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suggests again that advanced age per se, should not be a contra-
indication for allografting in MDS. Assessment scores such as the
Charlson comorbidity score, or more recently, the specifically devel-
oped hematopoietic cell transplantation comorbidity indexmay help
to improve patient selection,17-19 and comorbidity indices should be
incorporated as part of transplant registry data collection forms for
future studies.
The single most important prognostic variable in our study was
the disease stage at time of transplantation, with patients with more
than5%blasts at timeof transplantationhavinga significantly inferior
RFS andOS.Ourfindings are consistentwith reporteddata indicating
that in MDS/AML, a low pretransplant tumor burden is essential for
the success of the allograft.20-23 Intensive chemotherapy is effective in
inducing complete remissions in 15% to 65% of patients.23,24 How-
ever, these remissions are often short-lived due to subsequent disease
relapse.While itmay appear logical to pretreat patients with intensive
chemotherapy to reduce the disease burden, controversy remains
about the effectiveness of this approach, as it is unclear if intensive
chemotherapy merely identifies a subgroup of patients with more
chemotherapy-responsive treatment.
Theobservation that patients receiving SMChave a lower relapse
incidence when compared with patients receiving RIC in our cohort
supports existing evidence suggesting that the dose intensity of the
conditioning regimen has an important influence on the post-
transplant remission rates.12 However, recent data from Scott et al22
on 150 patients with MDS/sAML receiving RIC or SMC regimens
demonstrated that the overall andprogression-free survival rateswere
similar for patients with chemotherapy-induced remissions irrespec-
tive of conditioning intensity, suggesting that graft versus leukemia
effectsmaybemore important inpreventingprogression inpatients in
chemotherapy-induced remissions at the time of transplantation. In
contrast, Aylea and collegues11 have shown that increasing the dose
intensity of RIC regimens reduces the relapse incidence among pa-
tients with either MDS or AML, albeit with increased treatment re-
lated toxicity. Indeed, there is evidence to suggest that in selectedolder
patients, an intensification of the reduce intensity conditioning regi-
mensmaybe effective at treating patientswith active disease at timeof
transplantation.25,26 Unfortunately, the heterogeneity of the condi-
tioning regimens within the EBMT registry database limits any more
detailed analysis of this relationship.
While only 31% of patients in the cohort had available cytoge-
netic data, the presence of poor-risk cytogenetic features was associ-
ated with significantly inferior outcomes on multivariate analysis.
There were however notable differences in the patient demographics
of this group when compared with patients without any available
cytogenetic information, and as such the cytogenetic findings of this
study may not be extrapolated for the whole cohort of patients. Nev-
ertheless, this observation highlights the prognostic significance of
pretransplant cytogenetic evaluation and the need to consider specific
treatment strategies in patients with poor-risk cytogenetics.
Specificquestionsneed tobe addressedwith regards to the roleof
both induction chemotherapy, anddose-intensified reduced intensity
conditioning, and their associated toxicity in older patients under
consideration for allogeneic transplantation. Our study indicates that
in older patients with advanced disease stage at transplantation, alter-
native treatment options or novel treatment regimens should be con-
sidered. The recent discovery of novel immunomodulatory and
disease modifying agents has expanded the treatment options for a
Table 2. Multivariate Analysis for Outcomes
Variable Hazard Ratio 95% CI Overall P 
Overall survival
Recipient age, years .42
50-60 Referent
 60 1.07 0.90 to 1.27
Conditioning .51
Myeloablative Referent
RIC 0.95 0.80 to 1.11
Disease stage at transplantation  .01
Early Referent
Advanced 1.55 1.32 to 1.83
Donor 0.12
HLA-matched sibling Referent
HLA-matched unrelated 1.25 1.02 to 1.47 .05
HLA-mismatched unrelated 1.22 0.90 to 1.65 .19
Cytogenetics  .01
Standard/favorable risk Referent
Poor risk 1.73 1.27 to 2.36
Relapse
Recipient age, years .06
50-60 Referent
 60 1.42 0.99 to 2.04
Conditioning  .01
Myeloablative Referent
RIC 1.44 1.13 to 1.84
Disease stage at transplantation  .01
Early Referent
Advanced 1.51 1.18 to 1.93
Donor .83
HLA sibling Referent
HLA-matched unrelated 1.08 0.68 to 1.70 .75
HLA-mismatched unrelated 0.99 0.62 to 1.59 .98
Cytogenetics .03
Standard/favorable risk Referent
Poor risk 1.16 1.01 to 1.32
Nonrelapse mortality
Age, years .82
50-60 Referent
 60 0.96 0.67 to 1.36
Conditioning .03
Myeloablative Referent
RIC 0.79 0.65 to 0.97
Disease stage at transplantation .01
Early Referent
Advanced 1.43 1.13 to 1.79
Donor .03
HLA-matched sibling Referent
HLA-matched unrelated 1.57 1.10 to 2.24 .01
HLA-mismatched unrelated 1.31 0.91 to 1.87 .14
Cytogenetics .01
Standard/favorable risk Referent
Poor risk 1.18 1.04 to 1.34
NOTE. Reference variables were age: 50-60 years; conditioning: RIC; disease
stage at transplantation: advanced disease; donor type: HLA-matched sibling.
Abbreviation: RIC, reduced intensity conditioning.
Some risk factors in the Cox model contain a category for unknown to avoid
loss of information; the overall P values for age, conditioning, disease stage,
donor, and cytogenetics denote the P value of the complete risk factor; the
individual P values denote the P values of the given contrasts to the reference
category. For clarity, the unknown categories as well as the nonsignificant risk
factors have been omitted from the table.
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subset of patientswithMDS.27-29While the use of these agents, donot
result in a long-term cure, several recent studies have indicated the
feasibility of these agents in being incorporated into either the pre-
transplant induction regimen, or as part of the post-transplantation
maintenanceprotocol.30Given the relativelyhigh relapse rates in these
patients, the role of low toxicity agents as part of a pre-emptivemain-
tenance programwarrants further investigation.
The other major variable influencing outcomes in our study is
the choice of donor; allografting with anHLA-matched sibling donor
being associated with significantly reduced NRM when compared
with the use of an unrelated donor. Early registry analyses on the
results of MDS patients transplanted with unrelated donors (median
recipient age  38 years) demonstrated a 2-year NRM of 54% to
57%.2,3 Advances in supportive care and conditioning regimens have
contributed to the comparatively improvedNRMin this cohort (36%
at 4 years). Particularly in the context of RIC HSCT, various centers
have recently reportedon theuseof both sibling andunrelateddonors
with comparable outcomes.21,31 However, our data suggest that in
older patients with MDS, the choice of stem-cell donor remains a
point of consideration, although both types of donors result in signif-
icant long-term survival even in patients older than 60 years.
In summary, this study demonstrates that allogeneic HSCT is a
potential curative therapeutic option for many older patients with
MDS and that disease stage at time of transplantation, but not age,
remains themost important factor influencing subsequent outcomes.
In addition, the choice of stem-cell donor remains a significant con-
sideration for allogeneic transplantation within this age group of pa-
tients. Given the increasing choice of options within the field ofMDS
transplantation, an individualized approach should be adopted in
determining specific treatment strategies toward the treatment of a
patient withMDS.
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